Name: Fingolimod (FTY720) HCl
Brand: Selleck Chemicals
SKU: S5002
Rating: 5 (91 reviews)

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Selleck's Fingolimod (FTY720) HCl has been cited by 91 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Related Compound Libraries

Other S1P Receptor Products

Download Inhibitor Catalog

S1P Receptor Signaling Pathway Map

Biological Activity

Description

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Targets

S1P receptor ^[1]
(K562, NK cells )

0.033 nM

In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. ^[1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human U2OS cells	M{TQb2Z2dmO2aX;uJIF{e2G7			MkLpRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXAyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy\|IHPvMYV5eHKnc4Ppcoch\UeIUDDhd5Nme3OnZDDhd{Bz\WOncITvdkBqdnSncn7hcIl7[XSrb36gbY51dyCleYTvdIxie21idYPpcochUG:nY3jzeEBlgWVic4ThbY5qdmduIFXDOVA:OC5yMEKg{txONg>?	MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMESxOFQoRjJ{MUC0NVQ1RC:jPh?=
human PC3 cells	MWTDfZRwfG:6aXRCpIF{e2G7		MWO3NkBp	M4rGe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYOsJGlEPTB;OT64JO69VS5?	MkG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N\|IoRjJ2MkezOlMzRC:jPh?=
human NALM6 cells	MVrDfZRwfG:6aXRCpIF{e2G7		MWe3NkBp	MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBPSUyPNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9PU43KM7:TT6=	M4WzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N\|Y{OjxxYU6=
human CCRF-CEM cells	NITqWnREgXSxdH;4bYPDqGG\|c3H5		MoO5O\|IhcA>?	NUPnSmE{S3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uPEDPxE1w	NEfjT5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N\|Y{Oid-MkSyO\|M3OzJ:L3G+
human SUP-B15 cells	M2fHd2N6fG:2b4jpZ:Kh[XO\|YYm=		MmXUO\|IhcA>?	NGHDbGFEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3wc5NqfGm4ZTDoeY1idiCVVWCtRlE2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW\|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD14Lkig{txONg>?	NF24ZXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N\|Y{Oid-MkSyO\|M3OzJ:L3G+
human DU145 cells	NV\lXY9qS3m2b4TvfIlkyqCjc4PhfS=>		M1HvfVczKGh?	NVjzc41IS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N\|I9N2F-
human BV173 cells	NEW5SYREgXSxdH;4bYPDqGG\|c3H5		NEXN[Xo4OiCq	MmfUR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hSlZzN{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvOyEQvF2u	MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N\|IoRjJ2MkezOlMzRC:jPh?=
human BLIN-1 cells	MlT2R5l1d3SxeHnjxsBie3OjeR?=		NUXtdXl4PzJiaB?=	MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBDVEmQLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVUvPSEQvF2u	M37lW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N\|Y{OjxxYU6=
mouse bone marrow cells	MWLDfZRwfG:6aXRCpIF{e2G7		MnW4O\|IhcA>?	M1vQO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUj3BRmwh\nW\|aX;uJJBzd3SnaX6gNVkxKGW6cILld5NqdmdibX;1d4Uh[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuN{DPxE1w	M2rVZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N\|Y{OjxxYU6=
Sf9 insect cells	NY\XSVhCTnWwY4Tpc44h[XO\|YYm=		NYr5UIlXOSCq	NW\VXYZJUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTNXBNKCh4MjD0c{A2PjhrIHX4dJJme3OnZDDpckBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIGOxVEBieyC\|dXLzeJJifGViYX\0[ZIhOSCqch?=	NXH2PYc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFk5OTRpPkK0PFA6QDF2PD;hQi=>
mouse MN9D cells	MV\GeY5kfGmxbjDhd5NigQ>?	NWDkfHdQPSEQvF2=		MorFTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhifGVibHX2[Ywh[XRiNTD1US=>	M3nEPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwNVY2Lz5{NUC1NFE3PTxxYU6=
rat PC12 cells	Mnv4SpVv[3Srb36gZZN{[Xl?	NUm4[INLPSEQvF2=	NGPUe4g{OCC2bzCxNlAhdWmwcx?=	NVi5Sok2UW6mdXP0bY9vKG:oIGDQNmEh[2G2YXz5eIlkKHO3YoXubZQh[WO2aY\peJkhcW5icnH0JHBEOTJiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bp[XSnIHzleoVtKGG2IEWgeW0hdWWjc4Xy[YQhOzBidH:gNVIxKG2rboOu	NVzJZlRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
mouse MN9D cells	NHTaSFVHfW6ldHnvckBie3OjeR?=	MYOwMlE3KM7:TR?=	MWeyOEBp	NULITnFsVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO\|ZYPz[YQh[XNic4TpcZVt[XSrb36gc4YhSkSQRjDlfJBz\XO\|aX;uJIF1KDBwMU[geW0h[W[2ZYKgNlQhcHK\|	NGnwU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
mouse MN9D cells	MnL6SpVv[3Srb36gZZN{[Xl?	M1LOSFAvOTZizszN	MkfOO\|IhcA>?	M37yTW5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBud3W\|ZTDNUllFKGOnbHzzJIF{e2W\|c3XkJIF{KGKub3PrbY5oKG:oIGTOSk1idHCqYTDhd5Nw[2mjdHXkJJRwgGmlaYT5JIF1KDBwMU[geW0h[W[2ZYKgO\|IhcHK\|IHL5JHRzgXCjbjDicJVmKHO2YXnubY5oNg>?	MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUCxOlUoRjJ3MEWwNVY2RC:jPh?=
CHO	MmK2SpVv[3Srb36gZZN{[Xl?			MljuSIl{eGyjY3Xt[Y51KG:oIGuzN3Bee3CqaX7nc5NqdmViMTDwbI9{eGijdHWg[pJwdSCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9NE45PM7:TT6=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZzNUWxN{c,OTV4MUW1NVM9N2F-
CHO	M2HY[WZ2dmO2aX;uJIF{e2G7			NGHNWINFcXOybHHj[Y1mdnRib3[gX\|M{WF2\|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEWgdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0zNjIQvF2u	Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVMoRjF3NkG1OVE{RC:jPh?=
Jurkat	MU\GeY5kfGmxbjDhd5NigQ>?		MnK5NVghcHK\|	NGX0PIlT\X[ncoPhcEBw\iCrbnjpZol1cW:wIH;mJI1qfG:laH;u[JJq[WxiZoXuZ5Rqd25iaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IEG4JIhzeyCrbjDwdoV{\W6lZTDv[kBbNV[DRD3mcYs>	M4HDNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NECwOVU2Lz5zN{SwNFU2PTxxYU6=
T-cells	NYDNdmZmTnWwY4Tpc44h[XO\|YYm=		M4fqfVk3KGi{cx?=	NIPpSFNKdW23bn;zeZBxemW\|c3n2[UBi[3Srdnn0fUBqdiCEQVzCM4MwSzV5QlyvOkBud3W\|ZTDUJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzsc4FvfGmpZX6tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiOU[gbJJ{KGK7IH3lZZN2emmwZzDbN2hefGi7bXnkbY5mKHWydHHr[UBjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKGG\|c3H5MEBKSzVyPUCuNFA3Oc7:TT6=	MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
SK-BR-3	MoTYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3fFSVc5KGi{cx?=	MknSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSz3CVk0{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02\|ryPLh?=	NXu2TIV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
MDA-MB-231	NEX6WnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVvje4dEPzhiaILz	NYfNWHJySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21{txONg>?	NX;MfVZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
HCT116	NWnmPIxFSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M13ueFc5KGi{cx?=	MlvyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|ghcHK\|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SW620	Mne5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVnpWnNSPzhiaILz	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZNkKwJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21{txONg>?	M4ThfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MCF7	MoLBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXniUpR7PzhiaILz	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyPUZOwG0v	NXr3PWdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
LNCAP-AI	M3X2VGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoH0O\|ghcHK\|	M3TFPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIFzOR2FRNUGLIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd6IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD13zszNMi=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
MGC803	NVO1ZpNtSW62aYT1cY9zKGG\|c3H5	MWexNEBu\y:tZx?=	NVH1VWlyOjBiZHH5dy=>	NHjz[YdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMhgGWwb3fyZYZ1\WRiaX6gcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCxNEBu\y:tZzDmc5IhOjBiZHH5dy=>	M2rWelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
U2OS	M{m4VGZ2dmO2aX;uJIF{e2G7		NXqyNIE1OThiaILz	M2j5emFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gV\|FROSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gSWRIOS2kbHGgWVJQWyClZXzsd{BqdmO3YnH0[YQh\m:{IEG4JIhzeyCycnnvdkB1dyCJZX7CcIF7\XJic4Xid5Rz[XSnIHHk[Il1cW:wIHL5JIJmfGFvYYLy[ZN1cW5icnXjdpVqfG2nboSgZZN{[XluIFXDOVA:OC5yMEey{txONg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ6N{S4O{c,OjZ4OEe0PFc9N2F-
FL5.12A	NH7GVZpEgXSxdH;4bYNqfHliYYPzZZk>		NHvFTZM1QCCqcoO=	NFK3ZotEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMULBJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0zNjUQvF2u	NX3q[npCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O\|U2OzRpPkK3OFc2PTN2PD;hQi=>
SH-SY5Y	NFrhRmdEgXSxdH;4bYNqfHliYYPzZZk>		MmDENlQhcHK\|	M1jMVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTUQvF2u	M4n0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN\|EyPTxxYU6=
SK-N-SH	MnTSR5l1d3SxeHnjbZR6KGG\|c3H5		Ml\TNlQhcHK\|	M4j2c2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vU1igZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTYQvF2u	NVrzPFkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
U118MG	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=		M4PsfFI1KGi{cx?=	NFSwUphEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOTF6TVegZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPjIQvF2u	MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SH-SY5Y	MUjGeY5kfGmxbjDhd5NigQ>?			M1;0OGFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7	MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
U118MG	NInJSXdHfW6ldHnvckBie3OjeR?=			MXLB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGWxNVhOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjRW1RKGyndnXsJIF1KEWFMUCgZpkh\Gm{ZXP0JIludXWwb3Hzd4F6	MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SK-N-SH	NV7IbphMTnWwY4Tpc44h[XO\|YYm=			NEG4W2xC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIh2dWGwIGPLMW4uW0hiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>?	MnfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
HEK293	MkTLSpVv[3Srb36gZZN{[Xl?		MV6xPEBpenN?	NGXqRnBC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClQV3QJIxmfmWuIHH0JGVEOTBiYX\0[ZIhOThiaILzJIJ6KEOURT3y[ZNxd26\|aY\lJJJmdmmubHGgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	M{\qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN\|EyPTxxYU6=
SJ-GBM2	NWnLZnBJeUiWUzDhd5NigQ>?			M4\QSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NEjZZnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MlTvdWhVWyCjc4PhfS=>			M{myR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NWS2TmpbeUiWUzDhd5NigQ>?			NYS5V206eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	M2nMOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	MoPwdWhVWyCjc4PhfS=>			MnHXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NXe0VphqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MXjxTHRUKGG\|c3H5			MnvFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NWW0PIpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	Mnj4dWhVWyCjc4PhfS=>			M{Kwc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MVPxTHRUKGG\|c3H5			MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NVzoVpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NGrLNFhyUFSVIHHzd4F6			M1KzXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NHnVWXJyUFSVIHHzd4F6			M{\LUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	M1TCV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NX3CZpB[eUiWUzDhd5NigQ>?			NF;t[o9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NV3uTGRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NYPZNYh6eUiWUzDhd5NigQ>?			NELZco1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NUDVc4xLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NHu4fIFyUFSVIHHzd4F6			NGLXT5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NUPBVZZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	M{TtdJFJXFNiYYPzZZk>			M4TjWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M{\oTJFJXFNiYYPzZZk>			M{jBSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NHvvNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	NUPpUlI1eUiWUzDhd5NigQ>?			NGnsR\|lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NHLXPW1yUFSVIHHzd4F6			Mk\YdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	NH25O3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
FL5.12	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		M3vGV\|Q5KGi{cx?=	NVX4O\|NXS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJI9zKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTJwMd88UU4>	MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUK4PVgoRjNyMkmyPFk5RC:jPh?=
FL5.12	NUjTdWoyS3m2b4TvfIlkcXS7IHHzd4F6	NW\pcpZvOTBidV2=	NGK1PFU{KGi{cx?=	NHfGTlBEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{	NEPhb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
FL5.12	M2HC[mN6fG:2b4jpZ4l1gSCjc4PhfS=>	M2jmN\|IvPSC3TR?=	NXnWcoF5OyCqcoO=	M2[3dGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjc4Pld5Nm\CCjczD2ZYN2d2ynIH\vdo1ifGmxbjDheEAzNjVidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{	NEjqWYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
HepG2	NUT3O2t1eUiWUzDhd5NigQ>?			MmT4TIVxTzJiY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?=	NI\1WnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|M{KyPVU1PSd-M{OyNlk2PDV:L3G+
CHO	NIXOUJlHfW6ldHnvckBie3OjeR?=			NGG2PVVC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZYxkcXWvIH\seZgh[nliYXXxeY9zcW5vZHXybZZm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:Oi53MUG4Pe69VS5?	NV7DZmJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzF2OEW0M{c,S2iHTVLMQE9iRg>?
CHO	MoLPSpVv[3Srb36gZZN{[Xl?			Mne1RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA2KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVMvOTZ{MklOwG0v	MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|E1QDV2Lze+R4hGVUKOPD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin ; p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16	28717222 25344679
Immunofluorescence	NF-κB ; N-cadherin / Vimentin	28717222 25344679
Growth inhibition assay	Cell viability	28717222

In vivo

FTY720 is effective in Ph⁺ but not Ph^- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph⁺ ALL xenografts using an early disease model. Ph⁺ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph^- ALL xenografts. ^[3]

Protocol (from reference)

Cell Research:^[1]

Cell lines: Immature DCs
Concentrations: 10 nM
Incubation Time: 4 hours
Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 10⁵ cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
(Only for Reference)

Animal Research:^[3]

Animal Models: NOD/SCIDγc^−/− mice bearing ALL cells.
Dosages: 5 mg/kg/day, 10 mg/kg/day
Administration: Administered via i.p.
(Only for Reference)

References

[4] Nikolova Z, et al. Transpl Immunol. 2001, 8(4), 267-277.

+ Expand

Solubility (25°C)

In vitro	DMSO	69 mg/mL (200.63 mM)
	Water	69 mg/mL (200.63 mM)
	Ethanol	''69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	343.9
Formula	C₁₉H₃₃NO₂.HCl
CAS No.	162359-56-0
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

Download Fingolimod (FTY720) HCl SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03345940	Terminated	Drug: Fingolimod\|Drug: Dimethyl Fumarate	Relapsing Remitting Multiple Sclerosis	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta\|Patient-Centered Outcomes Research Institute\|Universita degli Studi di Genova	April 30 2017	Phase 4
NCT02575365	Terminated	Drug: 05 mg Fingolimod	Cognition\|Brain Volume Loss	Novartis Pharmaceuticals\|Novartis	February 16 2016	Phase 4
NCT02490930	Completed	Drug: Fingolimod	Glioblastoma\|Anaplastic Astrocytoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	July 2015	Early Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):